Vitamin D receptor polymorphisms and fortification efficacy

A systematic review and meta-analysis published in August 2022 examined 16 randomized controlled trials involving 2,994 participants and found no overall statistically significant effect of common vitamin D receptor, or VDR, polymorphisms on the rise in circulating 25-hydroxyvitamin D [25(OH)D] after supplementation. In other words, the major VDR variants did not reliably prevent serum vitamin D from increasing.

That does not make genetics irrelevant. It makes the question more precise. VDR gene variants may influence what tissues do with vitamin D—particularly bone—without substantially changing how much 25(OH)D appears in the bloodstream after intake. The distinction is easy to miss, commercially inconvenient, and central to any serious discussion of vitamin D fortification.

The vitamin D receptor is not a decorative label attached to a supplement bottle. It is a nuclear receptor that helps regulate gene expression after the active vitamin D metabolite binds to it. A change in the receptor may alter signaling, tissue response, or bone mineral outcomes. It does not automatically rewrite intestinal absorption, serum kinetics, or the basic pharmacology of cholecalciferol.

The genetic architecture of vitamin D receptor signaling

Vitamin D biology involves several stages that marketing language tends to compress into one vague promise of “better absorption.”

Dietary vitamin D, including vitamin D3 or cholecalciferol, enters the body and is processed through metabolic steps before its status is generally assessed by measuring serum 25(OH)D. This marker reflects circulating vitamin D stores more usefully than the active hormone itself, although it is not a direct measurement of vitamin D receptor activity in bone, muscle, immune cells, or other tissues.

The VDR gene is located on chromosome 12q13.1. Commonly studied single nucleotide polymorphisms include:

• FokI, identified as rs10735810 or rs2228570;
• BsmI, identified as rs1544410;
• ApaI, identified as rs7975232;
• TaqI, identified as rs731236.

These variants do not all operate in the same way. FokI is a coding-region variant associated with a change in the VDR protein and is often discussed in relation to receptor activity. BsmI, ApaI, and TaqI are located in or near non-coding regions and may be associated with gene regulation or linked genetic patterns. The exact molecular consequences are not interchangeable, despite the tendency of personalized-nutrition advertising to treat every SNP as a deterministic switch.

The receptor’s role is also tissue-specific. In bone, VDR signaling interacts with calcium absorption, osteoblast and osteoclast activity, and broader mineral homeostasis. In the intestine, vitamin D signaling contributes to the regulation of calcium transport. In immune tissues, the receptor participates in gene-expression pathways that are biologically plausible but considerably easier to oversell than to measure in a clinical endpoint.

This creates two separate questions:

1. Does a VDR genotype change the increase in serum 25(OH)D after vitamin D intake?

2. Does a VDR genotype change the physiological outcome produced by that vitamin D exposure?

The first question has relatively reassuring aggregate evidence. The second is more complicated, especially for bone mineral density and bone mineral content.

A normal rise in serum 25(OH)D does not prove a normal tissue response. It also does not prove the opposite. The receptor is where the biology becomes inconvenient.

What the supplementation trials actually show

The 2022 meta-analysis assessed whether VDR polymorphisms altered serum 25(OH)D response to vitamin D supplementation. Across 16 randomized controlled trials and 2,994 analyzed subjects, the overall association was not statistically significant.

That result matters because serum 25(OH)D is the endpoint most often used to justify claims about vitamin D response. If a genotype consistently blocked vitamin D metabolism or absorption, one would expect a reproducible difference in circulating 25(OH)D after supplementation. The pooled evidence did not show such a general effect across the major VDR variants examined.

The measured serum thresholds also need to be kept in view. A 25(OH)D concentration below 20 ng/mL, or approximately 50.1 nmol/L, is commonly treated as deficient in the supplied clinical framework. A concentration above 30 ng/mL is often described as normal or sufficient in this context. These categories describe circulating status. They do not function as a genetic report card.

A person with a VDR variant can move from a deficient to a higher serum 25(OH)D range after vitamin D intake. That increase is not invalid because the receptor genotype differs. Nor does the genotype establish that a higher dose is automatically required. The evidence does not support a blanket claim that common VDR variants prevent serum 25(OH)D from rising.

The pattern can be summarized more accurately:

This is the point at which the myth usually changes costumes. If a variant does not produce a large, consistent difference in serum 25(OH)D, advocates may shift the argument to “cellular utilization” or “receptor resistance.” Sometimes that is a legitimate hypothesis. Often it is simply a way to preserve a commercial conclusion after the serum data have declined to cooperate.

The serum marker is not the whole phenotype

The absence of a significant overall effect on serum 25(OH)D does not mean that all VDR genotypes have identical clinical consequences. It means the aggregate serum response was not consistently different across the analyzed trials.

The distinction becomes clearer in studies examining bone outcomes. In a randomized placebo-controlled trial involving healthy adolescent girls, BsmI and TaqI genotypes significantly influenced gains in bone area, bone mineral content, and bone mineral density after one year of vitamin D3 supplementation. The lowest increments were reported in the BB and tt genotypes.

That finding does not demonstrate that these genotypes make vitamin D3 ineffective. It suggests that the same vitamin D exposure may be associated with different skeletal outcomes depending on receptor genotype, at least in that study population and under those trial conditions.

The difference is not semantic. Serum 25(OH)D tells us how much circulating substrate is available. Bone mineral density reflects a long chain of processes involving mineral intake, calcium handling, endocrine regulation, skeletal growth or remodeling, physical development, baseline status, and receptor-mediated gene expression. A higher serum level can coexist with a different tissue response because concentration and action are related but not identical variables.

FokI provides another example. The FF genotype has been associated in certain populations with higher VDR activity, increased bone mineral density, and lower fracture risk. The phrase “in certain populations” should remain attached to the claim. Genetic associations are vulnerable to differences in ancestry, age, sex, environmental exposure, nutrient status, and study design. An association is not a universal physiological law.

The bone findings therefore support a cautious model:

• VDR variants may influence the downstream response to vitamin D signaling.
• The effect may be more visible in tissue outcomes than in serum 25(OH)D.
• Effects may differ by genotype, population, life stage, and endpoint.
• A genotype-associated difference in bone gain is not equivalent to a fixed vitamin D requirement.
• No single VDR SNP currently provides a sufficient basis for redesigning population fortification on its own.

That last point is the one most likely to be ignored. Public-health policy needs effects that are reproducible, large enough to matter, measurable at population scale, and relevant to the food vehicle being used. A statistically interesting receptor association is not automatically a fortification algorithm.

Why subgroup results complicate the headline

The meta-analysis found statistically significant interactions in subgroup analyses based on age, sex, body mass index, study duration, and ethnicity. This is where a clean headline—“VDR variants do not affect vitamin D response”—becomes too blunt.

The more accurate statement is that no statistically significant overall effect was observed, while some study characteristics modified the relationship between VDR polymorphisms and serum 25(OH)D response.

That distinction is not a technical footnote. It affects how researchers interpret heterogeneity between clinical trials. A genotype may appear neutral in a pooled population while producing a detectable difference under particular combinations of age, body composition, sex, ethnicity, baseline vitamin D status, dose, or intervention duration.

But subgroup interactions are not magic confirmation of personalized nutrition. They can also arise from smaller sample sizes, multiple comparisons, inconsistent study designs, and differences in how genotypes or serum outcomes were measured. The correct response is replication, not a new supplement package labelled for each allele.

Several variables deserve particular attention:

Age and life stage

Vitamin D requirements and bone biology change over the life course. An adolescent skeletal-growth study cannot be translated directly into postmenopausal osteoporosis care or a fortification strategy for older adults. The endpoint itself changes: bone accrual in youth is not the same biological problem as preventing bone loss later in life.

Sex

Sex-dependent interactions may reflect differences in bone remodeling, hormonal environment, body composition, or trial populations. They do not justify a simple rule that one sex needs a different vitamin D fortification level solely because of a VDR genotype.

Body mass index

Body size and adipose tissue distribution can affect circulating vitamin D pharmacokinetics and are frequently considered in vitamin D trials. A subgroup interaction involving BMI may reflect the broader metabolic context rather than a pure receptor effect. The receptor is not operating in a vacuum, despite the popularity of genetic explanations that pretend it is.

Ethnicity and population structure

Genotype frequencies and linkage patterns differ between populations. So do sunlight exposure, dietary patterns, baseline status, skin pigmentation, food access, and the prevalence of other health conditions. An association observed in one population may not transfer cleanly to another. This is one reason that genetic claims should be evaluated in the populations targeted by a policy, not merely imported from a convenient dataset.

Study duration

Bone outcomes may require longer observation than serum changes. A short intervention can detect a biochemical shift while missing a skeletal effect—or produce an apparent subgroup difference that does not persist. Duration is not a minor design detail when the claim concerns mineralization or fracture risk.

The phrase “genetic influence” is not a result. It is a prompt to ask: influence on serum concentration, receptor activity, bone density, fracture risk, or merely a subgroup statistic?

What this means for food fortification

The key policy question is not whether VDR polymorphisms exist. They do. The question is whether current evidence supports genotype-specific fortification requirements.

At present, it does not.

The available findings support broad fortification strategies designed around population-level vitamin D status, dietary patterns, deficiency prevalence, safety considerations, and the performance of the chosen food vehicle. They do not support routine VDR genotyping before implementing fortification programs.

The evidence is also incomplete in a particularly important way: it does not establish whether different fortification matrices interact differently with VDR polymorphisms. Biofortified dairy, fortified flour, edible oils, and other food vehicles may differ in dose distribution, co-nutrient context, consumption patterns, and adherence. The supplied evidence does not resolve whether these matrices produce genotype-specific effects.

That unknown matters because supplement trials are not identical to food fortification programs. A capsule taken at a defined dose under trial conditions provides a different exposure pattern from a staple food consumed irregularly across a population. The vehicle may affect consistency of intake and the relationship between vitamin D exposure and other nutrients, although the specific interaction with VDR variants remains unresolved.

A defensible fortification framework should therefore separate three layers of evidence:

1. Population biochemical response: Does the intervention improve serum 25(OH)D across the target population?

2. Clinical and functional outcomes: Does it improve relevant outcomes such as rickets prevention, bone mineral measures, or osteoporosis-related risk?

3. Genotype-specific heterogeneity: Are any subgroup differences large, reproducible, and actionable enough to justify different policy levels?

The first two layers can support policy without the third being fully mapped. Waiting for a complete genotype-by-food-matrix model would delay interventions that can address established deficiency. Conversely, using preliminary genetic associations to justify individualized public fortification would turn uncertainty into policy theater.

A practical research agenda would prioritize:

• trials with standardized measurement of VDR variants and serum 25(OH)D;
• reporting of baseline vitamin D status and dietary intake;
• consistent assessment of body mass index, age, sex, ethnicity, and intervention duration;
• separate analysis of serum outcomes and skeletal outcomes;
• direct comparison of fortified food matrices rather than assuming supplement findings transfer automatically;
• replication of bone mineral density and bone mineral content findings in larger, diverse populations.

The objective should be to identify effect sizes that matter, not merely associations that can be printed on a report.

Personalized nutrition: promising concept, premature prescription

Personalized nutrition often begins with a reasonable observation and ends with an unreasonable invoice.

The reasonable observation is that genetic variation can influence biology. VDR polymorphisms may modify receptor function, bone mineral outcomes, or the response to antiresorptive therapy. In postmenopausal women with osteoporosis, VDR variants including BsmI and ApaI have been reported to modulate responses to therapies such as ibandronate and raloxifene. That is clinically interesting and worth further study.

The unreasonable leap is to infer that a consumer can determine a precise genotype-specific vitamin D requirement from a commercial genetic panel. The current evidence does not support that level of certainty. A variant associated with a skeletal response in one setting does not automatically prescribe a higher dietary dose, a different food vehicle, or a particular serum target.

There are several reasons for restraint:

• The overall serum 25(OH)D response was not significantly different across genotypes in the pooled supplementation analysis.
• Subgroup interactions require replication and careful interpretation.
• Bone mineral outcomes are not interchangeable with serum concentration.
• VDR polymorphisms represent only one part of vitamin D metabolism and signaling.
• The available evidence does not define how specific fortification matrices interact with these variants.
• No routine genetic-testing requirement has been established for public fortification programs.

This does not make genetic research useless. It defines the standard it must meet. A clinically actionable genotype should improve decisions beyond what can already be achieved with serum testing, clinical history, dietary assessment, and established risk factors. If a genetic result cannot reliably change management, it is a biological clue—not a prescription.

The same principle applies to genotype-specific vitamin D requirements. Before assigning different intake recommendations to different alleles, researchers would need reproducible evidence linking genotype to meaningful outcomes, not simply a statistical difference in one subgroup. They would also need to determine whether the difference persists across food matrices, baseline status, age groups, and populations.

Until then, personalization remains a research direction rather than a settled fortification model.

The policy verdict: design for the population, investigate the receptor

VDR gene variants add useful complexity to vitamin D science, but complexity is not the same as proof of individualized requirements.

The strongest current conclusion is deliberately narrow: common VDR polymorphisms—including FokI, BsmI, ApaI, and TaqI—do not appear to produce a consistent overall difference in serum 25(OH)D response to vitamin D supplementation across the 16 randomized controlled trials included in the 2022 meta-analysis. Some variants may influence bone mineral density, bone mineral content, bone area, or treatment response in particular populations and clinical settings. Those findings deserve better trials, not louder marketing.

For food fortification, the practical route remains population-based. Improve vitamin D status where deficiency is documented, evaluate the chosen food vehicle, monitor serum outcomes and relevant clinical endpoints, and keep genetic subgroup research running in parallel. Do not pretend that one receptor polymorphism has already solved the policy problem.

The blunt verdict is this: VDR genotype may shape vitamin D biology downstream, but current evidence does not justify genotype-specific public fortification or routine genetic testing before vitamin D intake. Serum levels rise across major genotypes. Tissue responses may differ. Both facts can be true at once—and any claim that erases either one is selling a myth, not explaining a mechanism.